Lyell (LYEL) CSO Gary K. Lee Sells 1,457 Shares

What Happened Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma (LYEL), reported the sale of 1,457 shares on 2026-08-21. The shares were sold at $15.54 per share for total proceeds of $22,642. This was a sale—specifically an automatic disposition to cover tax withholding tied to the settlement of vested restricted stock units (RSUs)—rather than an intentional open-market investment decision.

Key Details

• Transaction date and price: 2026-08-21 at $15.54 per share (total $22,642).
• Transaction type: Sale (code S); disposition to cover tax withholding from vested RSUs (footnote F1).
• Footnote: “Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.”
• Shares owned after the transaction: Not disclosed in the filing.
• Filing: Reported on SEC accession 0001907345-26-000006, filed 2026-08-25 (filed within the standard two-business-day Form 4 window for an 8/21 transaction).

Context Automatic share sales to satisfy tax withholding on vested RSUs are common and generally considered administrative rather than a signal of insider sentiment. Purchases typically carry more weight for assessing insider conviction; this transaction appears to be a routine tax-related sale.